Is Panitumumab on the market?

Panitumumab, whose trade name is Vectibix, is a fully human monoclonal antibody specific for the epidermal growth factor receptor, which can also be called EGF receptor, EGFR, ErbB-1 and HER1. Panitumumab manufactured byAmgen and originally developed by Abgenix Inc is used to treat metastatic colorectal cancer expressing EGFR that is resistant to chemotherapy regimens containing fluoropyrimidine, oxaliplatin, and irinotecan.

The U.S. Food and Drug Administration (FDA) first approved panitumumab in September 2006 for the treatment of EGFR-expressing metastatic colorectal cancer in which the disease continues to progress despite prior treatment. The European Medicines Agency and Health Canada approved panitumumab in 2007 and 2008 respectively for the treatment of refractory EGFR-expressing metastatic colorectal cancer with non-mutated (wild-type) KRAS. Panitumumab is the first monoclonal antibody to demonstrate the use of KRAS as a predictive biomarker. In July 2009, the FDA updated the labels for two anti-EGFR monoclonal antibody drugs (panitumumab and cetuximab) used to treat metastatic colorectal cancer to include information about KRAS mutations.

It is understood that the original version of panitumumab has not yet been launched in China, and therefore it has not been covered by medical insurance. The price of the Hong Kong original version of panitumumab sold in Hong Kong, China100mg/5mL may be around RMB 9,000 (the price may fluctuate due to exchange rates). There are currently no generic drugs of Panitumumab on the market. If a patient has a need to purchase Panitumumab, please consult a medical consultant for specific prices and more drug information.